AgomAb Therapeutics NV: director David R Epstein bought 5,000 shares

What happened David R Epstein, a director of AgomAb Therapeutics NV, reported an open market purchase of 5,000 common shares at $8.90 per share on Oct 8, 2026, for a total of $44,500, per the Form 4 filed Oct 9, 2026.

Key details

• Transaction date and price: Oct 8, 2026, purchase at $8.90 per share.
• Total shares bought and value: 5,000 shares for $44,500.
• Shares owned after the transaction: not reported in the filing.
• Footnote: the filing notes the common shares may be represented by American Depositary Shares, each currently representing one common share (F1).
• Filing date and timeliness: Form 4 filed on Oct 9, 2026; no late filing indicated in the report.

Why it may matter

• This filing records a direct open market purchase by a company director; it does not involve options, gifts, or tax withholding transactions.
• A filing does not show why the insider traded or why the company acted.